Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I-B Study to Evaluate the Safety, Tolerability and Efficacy of IZN-6NVS for the Treatment of Atrophic Vaginitis or Desquamative Inflammatory Vaginitis

Next Previous
X
Search
Trial Profile

Phase I-B Study to Evaluate the Safety, Tolerability and Efficacy of IZN-6NVS for the Treatment of Atrophic Vaginitis or Desquamative Inflammatory Vaginitis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 May 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Centella asiatica/Echinacea purpurea/Sambucus nigra (Primary)
  • Indications Atrophic vaginitis; Vaginitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Izun Pharma

    • Most Recent Events

    • 12 Mar 2018 Status changed from recruiting to completed.
    • 14 Oct 2017 Results (n=21) assessing safety, tolerability and efficacy of IZN-6NVS vaginal cream, in the treatment of atrophic vaginitis (AV) and desquamative inflammatory vaginitis (DIV), were presented at the North American Menopause Society 2017 Annual Meeting.
    • 13 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top